Tremeau Pharmaceuticals

Tremeau Expands Pipeline with Novel Non-Opioid Compound for the Treatment of Acute Pain

Retrieved on: 
星期一, 十月 25, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Safety, US Foods, Medication, Deuterium, Osteoarthritis, Stomach, Pain, Myocardial infarction, History, Hydrogen, Food and Drug Administration, Hospital for Special Surgery, Ulcer, Randomness, Rheumatoid arthritis, Systematic review, Codeine, Etoricoxib, Paracetamol, Dose, Bleeding time, Dog, Food, Ibuprofen, Perforation, Rehabilitation, Stroke, Peptic ulcer disease, Bleeding, Department, USPTO, Risk, Arthritis, Hospital, Weill Cornell Medicine, PLOS, Nonsteroidal anti-inflammatory drug, Heart, Veni, vidi, vici, MD, Cmax, NSAID, DVT, FitzGerald dynasty, Gastrointestinal bleeding, Trémeau, Lancet, Diclofenac, Patient, FDA, Patent, Extrapyramidal system, Chronic pain, CNT, Pharmaceutical industry, Dietary supplement, TRM-362 (Deuterated Etoricoxib), Tremeau Pharmaceuticals, TRM-362 (DEUTERATED ETORICOXIB), TREMEAU PHARMACEUTICALS

Once issued, the patent will provide composition of matter patent protection for Tremeaus novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041.

Key Points: 
  • Once issued, the patent will provide composition of matter patent protection for Tremeaus novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041.
  • These studies suggest that TRM-362 could provide similar or greater acute pain efficacy when compared to non-enriched etoricoxib, potentially at a lower dose.
  • The surgical community would welcome a more potent non-opioid pain medication that does not carry the bleeding risk of traditional NSAIDs.
  • We will work proactively with FDA to design a product for acute pain that ensures access only for short-term use.

Tremeau Pharmaceuticals Will Advance Non-Opioid Pain Program with Investment from Gurnet Point Capital

Retrieved on: 
星期三, 十二月 9, 2020
Health, Other Science, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Gurnet Point, Massachusetts, Opioid, Pain management, TRM-201, Tremeau Pharmaceuticals

Gurnet Point Capital, a private investment firm focused on the healthcare and life sciences sectors, is Tremeaus primary investor.

Key Points: 
  • Gurnet Point Capital, a private investment firm focused on the healthcare and life sciences sectors, is Tremeaus primary investor.
  • TRM-201 could be this much-needed option, and the investment and support from Gurnet Point Capital will enable us to make our vision a reality.
  • We made this investment because we see an opportunity to provide a pain management option thats long overdue to the bleeding disorder community.
  • Tremeau is a Massachusetts-based pharmaceutical company focused on providing non-opioid pain treatments for well-defined patient populations with significant unmet needs.